K
28.09
-0.86 (-2.97%)
| Previous Close | 28.95 |
| Open | 28.74 |
| Volume | 346,678 |
| Avg. Volume (3M) | 788,262 |
| Market Cap | 2,049,755,392 |
| Price / Sales | 4.70 |
| Price / Book | 5.00 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 5.0 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 54.00 (Jefferies, 92.24%) | Buy |
| Median | 48.00 (70.88%) | |
| Low | 42.00 (Wells Fargo, 49.52%) | Buy |
| Average | 48.00 (70.88%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 29.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 29 Jul 2025 | 54.00 (92.24%) | Buy | 30.37 |
| Wells Fargo | 09 Jul 2025 | 42.00 (49.52%) | Buy | 28.80 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MALLEY THOMAS | - | 33.24 | -177,769 | -5,909,997 |
| PAOLINI JOHN F. | - | 32.72 | -29,325 | -959,514 |
| Aggregate Net Quantity | -207,094 | |||
| Aggregate Net Value ($) | -6,869,511 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 33.11 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MALLEY THOMAS | Director | 14 Aug 2025 | Sell (-) | 78,233 | 33.28 | 2,603,594 |
| MALLEY THOMAS | Director | 14 Aug 2025 | Option execute | 78,233 | - | - |
| MALLEY THOMAS | Director | 13 Aug 2025 | Sell (-) | 50,129 | 33.65 | 1,686,841 |
| MALLEY THOMAS | Director | 13 Aug 2025 | Option execute | 50,129 | - | - |
| MALLEY THOMAS | Director | 12 Aug 2025 | Sell (-) | 49,407 | 32.78 | 1,619,561 |
| MALLEY THOMAS | Director | 12 Aug 2025 | Option execute | 49,407 | - | - |
| PAOLINI JOHN F. | Officer | 06 Aug 2025 | Automatic sell (-) | 29,325 | 32.72 | 959,514 |
| PAOLINI JOHN F. | Officer | 06 Aug 2025 | Option execute | 29,325 | - | - |
| Date | Type | Details |
|---|---|---|
| 29 Jul 2025 | Announcement | Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution |
| 24 Jul 2025 | Announcement | Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 |
| 05 Jun 2025 | Announcement | Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis |
| 29 May 2025 | Announcement | Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |